PrimeDesign software for rapid and simplified design of prime editing guide RNAs
- PMID: 33589617
- PMCID: PMC7884779
- DOI: 10.1038/s41467-021-21337-7
PrimeDesign software for rapid and simplified design of prime editing guide RNAs
Abstract
Prime editing (PE) is a versatile genome editing technology, but design of the required guide RNAs is more complex than for standard CRISPR-based nucleases or base editors. Here we describe PrimeDesign, a user-friendly, end-to-end web application and command-line tool for the design of PE experiments. PrimeDesign can be used for single and combination editing applications, as well as genome-wide and saturation mutagenesis screens. Using PrimeDesign, we construct PrimeVar, a comprehensive and searchable database that includes candidate prime editing guide RNA (pegRNA) and nicking sgRNA (ngRNA) combinations for installing or correcting >68,500 pathogenic human genetic variants from the ClinVar database. Finally, we use PrimeDesign to design pegRNAs/ngRNAs to install a variety of human pathogenic variants in human cells.
Conflict of interest statement
J.K.J. has financial interests in Beam Therapeutics, Chroma Medicine (f/k/a YKY, Inc.), Editas Medicine, Excelsior Genomics, Pairwise Plants, Poseida Therapeutics, SeQure Dx, Inc., Transposagen Biopharmaceuticals, and Verve Therapeutics (f/k/a Endcadia). J.K.J.’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. J.K.J. is a co-inventor on patents and patent applications that describe various gene editing technologies. D.R.L. is a consultant and co-founder of Prime Medicine, Beam Therapeutics, Pairwise Plants, and Editas Medicine, companies that use genome editing. L.P. has financial interests in Edilytics and SeQure Dx, Inc. L.P.’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. All other authors declare no competing interests.
Figures



Similar articles
-
Sequential Activation of Guide RNAs to Enable Successive CRISPR-Cas9 Activities.Mol Cell. 2021 Jan 21;81(2):226-238.e5. doi: 10.1016/j.molcel.2020.12.003. Epub 2020 Dec 29. Mol Cell. 2021. PMID: 33378644 Free PMC article.
-
Screening of CRISPR/Cas base editors to target the AMD high-risk Y402H complement factor H variant.Mol Vis. 2019 Mar 16;25:174-182. eCollection 2019. Mol Vis. 2019. PMID: 30996586 Free PMC article.
-
Prime Editing Guide RNA Design Automation Using PINE-CONE.ACS Synth Biol. 2021 Feb 19;10(2):422-427. doi: 10.1021/acssynbio.0c00445. Epub 2021 Jan 19. ACS Synth Biol. 2021. PMID: 33464043 Free PMC article.
-
[CRISPR/CAS9, the King of Genome Editing Tools].Mol Biol (Mosk). 2017 Jul-Aug;51(4):582-594. doi: 10.7868/S0026898417040036. Mol Biol (Mosk). 2017. PMID: 28900076 Review. Russian.
-
Shooting the messenger: RNA-targetting CRISPR-Cas systems.Biosci Rep. 2018 Jun 21;38(3):BSR20170788. doi: 10.1042/BSR20170788. Print 2018 Jun 29. Biosci Rep. 2018. PMID: 29748239 Free PMC article. Review.
Cited by
-
Base editing: advances and therapeutic opportunities.Nat Rev Drug Discov. 2020 Dec;19(12):839-859. doi: 10.1038/s41573-020-0084-6. Epub 2020 Oct 19. Nat Rev Drug Discov. 2020. PMID: 33077937 Free PMC article. Review.
-
Regional Variation in Cardiovascular Genes Enables a Tractable Genome Editing Strategy.Circ Genom Precis Med. 2024 Apr;17(2):e004370. doi: 10.1161/CIRCGEN.123.004370. Epub 2024 Mar 20. Circ Genom Precis Med. 2024. PMID: 38506054 Free PMC article.
-
High-throughput evaluation of genetic variants with prime editing sensor libraries.Nat Biotechnol. 2024 Mar 12. doi: 10.1038/s41587-024-02172-9. Online ahead of print. Nat Biotechnol. 2024. PMID: 38472508
-
New hope and promise with CRISPR-Cas9 technology for the treatment of HIV.Funct Integr Genomics. 2025 May 24;25(1):108. doi: 10.1007/s10142-025-01613-1. Funct Integr Genomics. 2025. PMID: 40411669 Review.
-
Future Perspectives of Prime Editing for the Treatment of Inherited Retinal Diseases.Cells. 2023 Jan 29;12(3):440. doi: 10.3390/cells12030440. Cells. 2023. PMID: 36766782 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials